Role of Innate Oral Immunity and Salivary Fluid in IBD: CMGH | April 2026

Introduction

Inflammatory bowel disease is increasingly understood as a disorder shaped not only by the gut itself, but also by extraintestinal immune and microbial influences. The oral cavity is one such important site because it is closely linked to the gut through swallowed saliva, oral microbes, and immune mediators. While the contribution of oral adaptive immunity and oral dysbiosis to IBD has been explored previously, the role of oral innate immunity, especially salivary fluid and its bioactive components, has remained unclear. This study examined whether saliva influences the oral microbiome, gut microbiome, gut barrier, and the course of colitis.

Problem statement

The key unanswered question was whether salivary innate immunity protects the gut or worsens intestinal inflammation, and through what mechanism this effect occurs.

Summary

This study showed that saliva has surprisingly little influence on the oral microbiome, but it has a clear effect on the gut environment and the severity of colitis. Using two mouse models with reduced salivation, the authors found that lack of saliva delayed the early development of DSS-induced colitis, suggesting that some salivary factors may initially worsen inflammation. However, once disease progressed, these mice developed rapid weight loss and higher mortality, indicating that saliva also contains protective components essential for later gut stability and survival.

The most important mechanistic insight was that saliva acts mainly through the gut barrier rather than by major reshaping of the microbiome. Mass spectrometry identified two key salivary molecules with opposing roles. Trefoil factor 2 (TFF2) acted as a protective peptide, helping preserve gut barrier integrity and reducing colitis severity. In contrast, macrophage migration inhibitory factor (MIF) acted as a damaging cytokine that worsened inflammation. Neutralizing TFF2 aggravated colitis, whereas neutralizing MIF was protective.

Overall, the study proposes that oral innate immunity is an important upstream regulator of gut inflammation. Saliva is not merely a digestive fluid; it carries immunologically active molecules that can either protect or damage the intestine depending on the disease stage. Clinically, this opens an interesting therapeutic concept: reducing salivary MIF or enhancing TFF2 may become a novel strategy for IBD treatment.